BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31921377)

  • 1. Combining Prostate-Specific Antigen Parameters With Prostate Imaging Reporting and Data System Score Version 2.0 to Improve Its Diagnostic Accuracy.
    Baruah SK; Das N; Baruah SJ; Rajeev TP; Bagchi PK; Sharma D; Phukan M
    World J Oncol; 2019 Dec; 10(6):218-225. PubMed ID: 31921377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of the prostate health index vs. multiparametric magnetic resonance imaging for prostate cancer diagnosis in prostate biopsy.
    Stejskal J; Adamcová V; Záleský M; Novák V; Čapoun O; Fiala V; Dolejšová O; Sedláčková H; Veselý Š; Zachoval R
    World J Urol; 2021 Jun; 39(6):1889-1895. PubMed ID: 32761380
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
    Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI.
    Liang L; Qi F; Cheng Y; Zhang L; Cao D; Cheng G; Hua L
    Sci Rep; 2021 Mar; 11(1):6048. PubMed ID: 33723287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml
    Wang C; Wang YY; Wang SY; Ding JX; Ding M; Ruan Y; Wang XH; Jing YF; Han BM; Xia SJ; Jiang CY; Zhao FJ
    Asian J Androl; 2021; 23(4):415-420. PubMed ID: 33473011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
    Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
    Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified Predictive Model and Nomogram by Incorporating Prebiopsy Biparametric Magnetic Resonance Imaging With Clinical Indicators for Prostate Biopsy Decision Making.
    Pan JF; Su R; Cao JZ; Zhao ZY; Ren DW; Ye SZ; Huang RD; Tao ZL; Yu CL; Jiang JH; Ma Q
    Front Oncol; 2021; 11():740868. PubMed ID: 34589437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New model of PIRADS and adjusted prostatespecific antigen density of peripheral zone improves the detection rate of initial prostate biopsy: a diagnostic study.
    Huang C; Cai ZQ; Qiu F; Pu JX; Xi QL; Wei XD; Wang XM; Zhao XJ; Guo LC; Hou JQ; Huang YH
    Asian J Androl; 2023; 25(1):126-131. PubMed ID: 35488668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and prostate multiparametric magnetic resonance imaging findings as predictors of general and clinically significant prostate cancer risk: A retrospective single-center study.
    Massanova M; Vere R; Robertson S; Crocetto F; Barone B; Dutto L; Ahmad I; Underwood M; Salmond J; Patel A; Celentano G; Bhatt JR
    Curr Urol; 2023 Sep; 17(3):147-152. PubMed ID: 37448611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
    Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
    Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.
    Wang S; Kozarek J; Russell R; Drescher M; Khan A; Kundra V; Barry KH; Naslund M; Siddiqui MM
    Eur Urol Oncol; 2024 Apr; 7(2):189-203. PubMed ID: 37640584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of the diagnostic accuracy across prostate health index, prostate health index density, and percentage free prostate-specific antigen for clinically significant prostate cancer: a prospective diagnostic study.
    Wu B; Shao Y; Lin X; Hasi C; Jia W; Wang D; Cao X
    Transl Androl Urol; 2023 Mar; 12(3):425-432. PubMed ID: 37032752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels.
    Tarcan T; Ozveri H; Biren T; Türkeri L; Akdas A
    Int J Urol; 1997 Jul; 4(4):362-7. PubMed ID: 9256325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When to biopsy Prostate Imaging and Data Reporting System version 2 (PI-RADSv2) assessment category 3 lesions? Use of clinical and imaging variables to predict cancer diagnosis at targeted biopsy.
    Lim CS; Abreu-Gomez J; Leblond MA; Carrion I; Vesprini D; Schieda N; Klotz L
    Can Urol Assoc J; 2021 Apr; 15(4):115-121. PubMed ID: 33007183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of prostate cancer using prostate imaging reporting and data system score and prostate-specific antigen density in biopsy-naive and prior biopsy-negative patients.
    Ryoo H; Kang MY; Sung HH; Chang Jeong B; Seo SI; Jeon SS; Lee HM; Jeon HG
    Prostate Int; 2020 Sep; 8(3):125-129. PubMed ID: 33102394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen density as the best predictor of low- to intermediate-risk prostate cancer: a cohort study.
    Park DH; Yu JH
    Transl Cancer Res; 2023 Mar; 12(3):502-514. PubMed ID: 37033352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone.
    Liu J; Dong B; Qu W; Wang J; Xu Y; Yu S; Zhang X
    Sci Rep; 2020 Mar; 10(1):5157. PubMed ID: 32198373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.